Upgrade to SI Premium - Free Trial

Imprimis Pharma (IMMY) Reports Q3 Loss of $0.28, Miss on Revenues

November 14, 2017 4:05 PM

Imprimis Pharma (NASDAQ: IMMY) reported Q3 EPS of ($0.28), versus $0.00 reported last year. Revenue for the quarter came in at $6.5 million versus the consensus estimate of $6.86 million.

Third Quarter 2017 and Recent Financial Highlights:

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

Categories

Earnings Guidance